EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Low‐intensity focused ultrasound neuromodulation for drug‐resistant epilepsy: A randomized, sham‐controlled crossover trial

Chien-Chen Chou iD, Yen-Cheng Shih iD, Yi-Hsiu Chen iD, Po-Tso Lin iD, Chun-Fu Lin iD, Po-Chun Chu iD, Hao-Li Liu iD, Cheng-Chia Lee iD, Hsiang-Yu Yu iD

Epilepsia · 2026-11 · 67 (11) · 5715-5728

DOI: 10.1002/epi.70404 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 01.08.2026. Verfasst von Chien-Chen Chou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Ultrasonic Therapy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NaviFUS Corp, National Health Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to evaluate the safety, feasibility, and efficacy of low‐intensity focused ultrasound (LIFU) as a noninvasive neuromodulation technique in patients with drug‐resistant epilepsy (DRE).

Methods

In this pilot, single‐blind, randomized sham‐controlled crossover trial, 12 patients with DRE underwent both LIFU and sham stimulation in a randomized sequence, targeting the seizure onset zone (SOZ), each followed by a 4‐week observation period. Seizure frequency was analyzed as proportional change from baseline using linear mixed‐effects models. An open‐label extension phase evaluated longitudinal seizure outcomes following LIFU. Safety assessments included neurological examinations, magnetic resonance imaging (MRI), and neuropsychological and quality of life (QOL) measures.

Results

During the crossover phase, LIFU did not significantly reduce seizure frequency compared with sham (estimate = .49, 95% confidence interval [CI] = −.04 to 1.01, p = .068). No period or sequence effects were observed. Conversely, during the open‐label extension phase, seizure frequency demonstrated a significant longitudinal reduction following LIFU (β = −14.0 percentage points per month, 95% CI = −22.2 to −5.8, p = .001). Post‐LIFU MRI showed no structural lesions. No significant changes were observed in anxiety, depression, or QOL scores. There were only transient mild‐to‐moderate adverse events reported, without serious complications. Significance LIFU neuromodulation targeting the SOZ is safe and well tolerated. Although the primary crossover analysis did not demonstrate a statistically significant antiseizure effect, delayed seizure reduction during the extended follow‐up suggests potential sustained neuromodulatory effects. Larger parallel‐group trials with longer observation periods are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyUltrasonic TherapyHumansCross-Over StudiesFemaleMaleAdultSingle-Blind MethodTreatment OutcomeQuality of LifePilot ProjectsYoung AdultMagnetic Resonance ImagingMiddle AgedAdolescent

Stichwörter der Autor:innen

crossover trialepilepsyfocused ultrasoundneuromodulationnoninvasive brain stimulation

Autor:innen und Institutionen

  • Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.
  • Brain Research Center, National Yang-Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan.

ORCID-Profile: Chien-Chen Chou, Yen-Cheng Shih, Yi-Hsiu Chen, Po-Tso Lin, Chun-Fu Lin, Po-Chun Chu, Hao-Li Liu, Cheng-Chia Lee, Hsiang-Yu Yu

Förderung

  • NaviFUS Corp
  • National Health Research Institutes

Zitieren

APA

Chou, C. C., Shih, Y. C., Chen, Y. H., Lin, P. T., Lin, C. F., Chu, P. C., Liu, H. L., Lee, C. C., & Yu, H. Y. (2026). Low‐intensity focused ultrasound neuromodulation for drug‐resistant epilepsy: A randomized, sham‐controlled crossover trial. Epilepsia, 67(11), 5715-5728. https://doi.org/10.1002/epi.70404

Vancouver

Chou CC, Shih YC, Chen YH, Lin PT, Lin CF, Chu PC, et al. Low‐intensity focused ultrasound neuromodulation for drug‐resistant epilepsy: A randomized, sham‐controlled crossover trial. Epilepsia. 2026;67(11):5715-5728. doi:10.1002/epi.70404

BibTeX
@article{Chou2026,
  author = {Chou, Chien-Chen and Shih, Yen-Cheng and Chen, Yi-Hsiu and Lin, Po-Tso and Lin, Chun-Fu and Chu, Po-Chun and Liu, Hao-Li and Lee, Cheng-Chia and Yu, Hsiang-Yu},
  title = {Low‐intensity focused ultrasound neuromodulation for drug‐resistant epilepsy: A randomized, sham‐controlled crossover trial},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {5715--5728},
  doi = {10.1002/epi.70404}
}
Kostenlos starten →